Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series

A. Nigrović, Peter; L. Mannion, Melissa; H. M. Prince, Femke; Zeft, Andrew; Egla Rabinovich, C.; A. J. van Rossum, Marion; Cortis, Elisabetta; Pardeo, Manuela; Miettunen, Päivi; Janow, Ginger; Birmingham, James; T Eggebeen, Aaron; Janssen, Erin; I. Shulman, Andrew; Beth F. Son, Mary; Hong, Sandy; Jones, Karla; T. Ilowite, Norman; Q. Cron, Randy; C. Higgins, Gloria

doi:10.1002/art.30128

Public

Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series

Published in Arthritis & Rheumatism • Nov 6, 2010

Authors:

Peter A. Nigrović

Melissa L. Mannion

Femke H. M. Prince

Abstract

OBJECTIVE: To examine the safety and efficacy of the interleukin-1 (IL-1) receptor antagonist anakinra as first-line therapy for systemic juvenile idiopathic arthritis (JIA). METHODS: Patients with systemic JIA receiving anakinra as part of initial disease-modifying antirheumatic drug (DMARD) therap...

Subject

Anakinra

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!